Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Pratibha Bhatia, MSc, BSc, Sumeet Prakash Mirgh, MBBS,MDDM, Vishvdeep Khushoo, MBBS,MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Rayaz Ahmed, MDDM, Narendra Agrawal, MD DM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 3500.

https://doi.org/10.1182/blood-2019-131763

Published: 2019

Journal Articles

Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Ashraf T Soliman, MDFRCP PhD, Vincenzo Desanctis, MD, Sandara Abusamaan, MD, Ahmed Elsotouhy, MD, Nader Aldewik, MSc PhD

Blood (2014) 124 (21): 4891.

https://doi.org/10.1182/blood.V124.21.4891.4891

Published: 2014

Journal Articles

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Wang Lining, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Yu Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Saijuan Chen, Zhenyi Wang, Junmin Li, MD PhD

Blood (2014) 124 (21): 282.

https://doi.org/10.1182/blood.V124.21.282.282

Published: 2014

Journal Articles

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

Craig H. Moskowitz, MD, Anas Younes, MD, Sven de Vos, MD, PhD, R. Gregory Bociek, MD, Leo I. Gordon, MD, Thomas E. Witzig, MD, Randy D. Gascoyne, MD, Brian West, Ph.D., Keith Nolop, MD, Christian Steidl, MD

Blood (2012) 120 (21): 1638.

https://doi.org/10.1182/blood.V120.21.1638.1638

Published: 2012

Journal Articles

High Incidence of Fanconi Anemia in Patients with a Morphological Picture Consistent with Refractory Cytopenia of Childhood

Ayami Yoshimi, MD, PhD,, Charlotte M. Niemeyer, MD, Irith Baumann, M.D., Stephan Schwarz-Furlan, MD, Detlev Schindler, MD, Wolfram Ebell, MD, Brigitte Strahm, MD

Blood (2011) 118 (21): 2780.

https://doi.org/10.1182/blood.V118.21.2780.2780

Published: 2011

Journal Articles

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation In Chinese Patients with Chronic Myelogenous Leukemia.

Yingjia Wang, Yanmin Zhao, Lizhen Liu, Weijie Cao, Kangni Wu, Longyan Chen, Xiaohong Yu, He Huang, MD, PhD

Blood (2010) 116 (21): 4475.

https://doi.org/10.1182/blood.V116.21.4475.4475

Published: 2010

Journal Articles

Skin Changes on Continued Imatinib Therapy in Patients with Ph+ CML.

Tapan Saikia, MD, Nandini Hazarika, MD, Boman Dhabhar, MD

Blood (2007) 110 (11): 2963.

https://doi.org/10.1182/blood.V110.11.2963.2963

Published: 2007

Journal Articles

Puvatherapy in the Management of Graft-Versus-Host Disease: Brazilian Experience.

Luis Fernando Bouzas, MD, MSc, Marcia M. Silva, Ph.D., Decio Lerner, MD, Rita de Cassia B. Tavares, MD, Alexandre M. Azevedo, MD, MSc, Absalom L. Filgueira, Ph.D.

Blood (2006) 108 (11): 5323.

https://doi.org/10.1182/blood.V108.11.5323.5323

Published: 2006

Journal Articles

A Prospective Analysis of Adverse Events in a Phase 2 Trial of Imatinib in the Treatment of Polycythemia Vera.

C. Michael Jones, MD, Tina M. Dickinson, MSN, FNP

Blood (2005) 106 (11): 4951.

https://doi.org/10.1182/blood.V106.11.4951.4951

Published: 2005

Journal Articles

Patterns of Relapse and Toxicity in Patients of CML (Chronic Phase) on Imatinib Therapy.

Shyam Aggarwal, Atul Gogia, Meena Lal, Sarjana Dutt, Manorama Bhargava

Blood (2005) 106 (11): 4858.

https://doi.org/10.1182/blood.V106.11.4858.4858

Published: 2005

Journal Articles

Successful Treatment of Cutaneous Chronic Lymphocytic Leukemia with a Topical Toll Receptor 7/8 Antagonist (Imiquimod).

Lisa Hicks, J. Mena, D. E. Spaner

Blood (2004) 104 (11): 4832.

https://doi.org/10.1182/blood.V104.11.4832.4832

Published: 2004

NARROW

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Hereditary Hemochromatosis in an Adult Due to H63D Mutation: The Value of Estimating Iron Deposition By MRI T2* and Dissociation Between Serum Ferritin Concentration and Hepatic Iron Overload

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial

High Incidence of Fanconi Anemia in Patients with a Morphological Picture Consistent with Refractory Cytopenia of Childhood

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation In Chinese Patients with Chronic Myelogenous Leukemia.

Skin Changes on Continued Imatinib Therapy in Patients with Ph+ CML.

Puvatherapy in the Management of Graft-Versus-Host Disease: Brazilian Experience.

A Prospective Analysis of Adverse Events in a Phase 2 Trial of Imatinib in the Treatment of Polycythemia Vera.

Patterns of Relapse and Toxicity in Patients of CML (Chronic Phase) on Imatinib Therapy.

Successful Treatment of Cutaneous Chronic Lymphocytic Leukemia with a Topical Toll Receptor 7/8 Antagonist (Imiquimod).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only